



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

10th March, 2023

Corporate Relationship Department
M/s. BSE Ltd.
Dalal Street, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Please find enclosed herewith the disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for your information.

Thanking you,

Yours faithfully
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/21/2022-23

10th March, 2023

NATCO announces the Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the USA

Hyderabad, India, 10th March, 2023

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announces the launch of additional strengths for the generic version of Revlimid® (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States, through its marketing partner Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.

With this launch the companies made available all the strengths of lenalidomide in the US market. Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.

Revlimid® is a registered trademark of Celgene Corporation, a Bristol-Myers Squibb Company.

For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer